BRD2 and cancer: AT1 significantly degraded BRD4 (DC50 = 10-100 nM, Dmax > 90%) in all tested cancer cells; however, it showed negligible activity against BRD2 and BRD3, suggesting that AT1 demonstrated a greater degree of selectivity in its ability to deplete BRD4 compared to MZ1.